My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).
To keep patients at the center of our process, the Max team asked patient leaders and associations from around the world to send in their own questions about TFR. We compiled their submissions, identified common themes, and narrowed the field down to 10 key questions.
Download the My PCR Treatment-Free Remission FAQ (PDF)
The answers in the FAQ were provided by CML expert, Max Medical Advisor, and friend of the organization, Dr. Michael J. Mauro of Memorial Sloan Kettering Cancer Center. Thanks to his extensive knowledge and experience, the document offers valuable information for patients and providers alike.
This FAQ marks another new resource created by The Max Foundation’s My PCR initiative – a global effort to increase access to polymerase chain reaction (PCR) testing for CML.
The Max Foundation extends its thanks to all the generous sponsors who make the My PCR initiative possible:
With their support we’re expanding access to critical diagnostics in low- and middle-income countries around the world.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Watch webinar on “Overcoming Barriers to Pediatric Cancer Care in Nepal” Last October I had the privilege of visiting Patan Hospital in Nepal on behalf of The Max Foundation. Right then, I knew I would dedicate my next birthday to supporting people in need of cancer treatment in the country by covering the cost of diagnostics….
Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD join the board this March
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….
